Sarepta Therapeutics (NASDAQ:SRPT) Downgraded by BidaskClub

BidaskClub cut shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research report released on Saturday, January 6th.

A number of other analysts have also recently commented on SRPT. Leerink Swann reissued an outperform rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, September 30th. Instinet restated a buy rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. JPMorgan Chase & Co. restated a hold rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They issued a buy rating and a $75.00 price objective for the company. Finally, Credit Suisse Group restated an outperform rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $63.88.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at $60.15 on Friday. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $3,890.00, a PE ratio of -29.49 and a beta of 1.37. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $62.85.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the firm posted ($0.95) EPS. analysts predict that Sarepta Therapeutics will post -3.07 EPS for the current fiscal year.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram bought 38,138 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the transaction, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of SRPT. Ameritas Investment Partners Inc. raised its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the period. Cubist Systematic Strategies LLC raised its position in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its position in Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 2,493 shares during the period. Fox Run Management L.L.C. purchased a new stake in Sarepta Therapeutics in the 3rd quarter worth about $204,000. Finally, Bayesian Capital Management LP purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth about $206,000. 82.02% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics (NASDAQ:SRPT) Downgraded by BidaskClub” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://baseballnewssource.com/markets/sarepta-therapeutics-srpt-rating-lowered-to-hold-at-bidaskclub/1822184.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.